These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33965414)

  • 1. Complications of Preseptal Versus Pretarsal Botulinum Toxin Injection in Benign Essential Blepharospasm: A Randomized Controlled Trial.
    Sanguandikul L; Apinyawasisuk S; Jariyakosol S; Hirunwiwatkul P; Chongpison Y
    Am J Ophthalmol; 2021 Dec; 232():9-16. PubMed ID: 33965414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques.
    Lolekha P; Choolam A; Kulkantrakorn K
    Neurol Sci; 2017 Nov; 38(11):2031-2036. PubMed ID: 28884242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tear production and drainage after botulinum toxin A injection in patients with essential blepharospasm.
    Park DI; Shin HM; Lee SY; Lew H
    Acta Ophthalmol; 2013 Mar; 91(2):e108-12. PubMed ID: 23425111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Safety and Efficacy of Botox and Neuronox in the Management of Benign Essential Blepharospasm: A Split-face Study.
    Sane S; Ali MJ; Naik MN
    Korean J Ophthalmol; 2019 Oct; 33(5):430-435. PubMed ID: 31612653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of benign essential blepharospasm on dry eye disease and ocular inflammation.
    Lu R; Huang R; Li K; Zhang X; Yang H; Quan Y; Li Q
    Am J Ophthalmol; 2014 Mar; 157(3):591-7.e1-2. PubMed ID: 24269849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increase lipid tear thickness after botulinum neurotoxin A injection in patients with blepharospasm and hemifacial spasm.
    Ho RW; Fang PC; Chao TL; Chien CC; Kuo MT
    Sci Rep; 2018 May; 8(1):8367. PubMed ID: 29849166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tear osmolarity, dry eye syndrome, blepharospasm and botulinum neurotoxin.
    Girard B; de Saint Sauveur G
    J Fr Ophtalmol; 2021 Dec; 44(10):1553-1559. PubMed ID: 34756743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corneal and Tear Film Changes After Botulinum Toxin-A in Blepharospasm or Hemifacial Spasm.
    Gunes A; Demirci S; Koyuncuoglu HR; Tok L; Tok O
    Cornea; 2015 Aug; 34(8):906-10. PubMed ID: 26075455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum neurotoxin A injection for the treatment of epiphora with patent lacrymal ducts.
    Girard B; Piaton JM; Keller P; Nguyen TH
    J Fr Ophtalmol; 2018 Apr; 41(4):343-349. PubMed ID: 29681465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of tear abnormalities associated with benign essential blepharospasm and amelioration by means of botulinum toxin type A treatment.
    Hosotani Y; Yokoi N; Okamoto M; Ishikawa H; Komuro A; Kato H; Mimura O; Gomi F
    Jpn J Ophthalmol; 2020 Jan; 64(1):45-53. PubMed ID: 31823132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects.
    Mitsikostas DD; Dekundy A; Hanschmann A; Althaus M; Scheschonka A; Pagan F; Jankovic J
    Curr Med Res Opin; 2021 Oct; 37(10):1761-1768. PubMed ID: 34384301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
    Ababneh OH; Cetinkaya A; Kulwin DR
    Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Two Botulinum Neurotoxin A Injection Patterns with or without the Medial Lower Eyelid in the Treatment of Blepharospasm.
    Yang H; Lu J; Zhao X; Ding X; Wang Z; Cai X; Luo Y; Lu L
    J Ophthalmol; 2016; 2016():5957812. PubMed ID: 26885381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High versus low concentration botulinum toxin A for benign essential blepharospasm: does dilution make a difference?
    Boyle MH; McGwin G; Flanagan CE; Vicinanzo MG; Long JA
    Ophthalmic Plast Reconstr Surg; 2009; 25(2):81-4. PubMed ID: 19300145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A direct comparison of onabotulinumtoxina (Botox) and IncobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm: a split-face technique.
    Saad J; Gourdeau A
    J Neuroophthalmol; 2014 Sep; 34(3):233-6. PubMed ID: 24739994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preseptal and Pretarsal Botulinum Toxin Injection in Hemifacial Spasm and Blepharospasm: A 10-Year Comparative Study.
    Teekaput C; Teekaput K; Thiankhaw K
    Ther Clin Risk Manag; 2023; 19():35-42. PubMed ID: 36660550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combined treatment with orbital and pretarsal botulinum toxin injections in the management of poorly responsive blepharospasm.
    Esposito M; Fasano A; Crisci C; Dubbioso R; Iodice R; Santoro L
    Neurol Sci; 2014 Mar; 35(3):397-400. PubMed ID: 23949734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of individualized botulinum neurotoxin type A injection techniques in patients with essential blepharospasm.
    Sung Y; Nam SM; Lew H
    Korean J Ophthalmol; 2015 Apr; 29(2):115-20. PubMed ID: 25829828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin for benign essential blepharospasm: A systematic review and an algorithmic approach.
    Rayess YA; Awaida CJ; Jabbour SF; Ballan AS; Sleilati FH; Abou Zeid SM; Nasr MW
    Rev Neurol (Paris); 2021; 177(1-2):107-114. PubMed ID: 32654779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocular surface alterations in blepharospasm patients treated with botulinum toxin A injection.
    Kocabeyoglu S; Sekeroglu HT; Mocan MC; Muz E; Irkec M; Sanac AS
    Eur J Ophthalmol; 2014; 24(6):830-4. PubMed ID: 24803156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.